{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-203530","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.748867+00:00","generated_at":"2026-05-17T06:42:34.778965+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout","bullets":["Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.","Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.","OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.","CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-203530","json":"https://secwatch.observer/filing/0001193125-25-203530.json","markdown":"https://secwatch.observer/filing/0001193125-25-203530.md","text":"https://secwatch.observer/filing/0001193125-25-203530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000119312525203530/0001193125-25-203530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000119312525203530/opk-20250915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:42:34.778965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}